目的 探討健脾生血片聯(lián)合羅沙司他治療慢性腎病非透析患者腎性貧血的臨床療效。方法 選取2020年11月-2022年11月河南宏力醫(yī)院接收治療的130例慢性腎臟病3~5期非透析腎性貧血患者,隨機(jī)法分對照組(65例)和治療組(65例)。對照組患者口服羅沙司他膠囊,70 mg/次(40~60 kg),100 mg/次(≥ 60 kg),3次/周。在對照組治療基礎(chǔ)上,治療組口服健脾生血片,3片/次,3次/d。兩組用藥12周。觀察兩組患者臨床療效,比較治療前后兩組患者癥狀緩解時間,紅細(xì)胞(RBC)、紅細(xì)胞比值(HT)、血紅蛋白(Hb)、血清鐵蛋白(SF)、白細(xì)胞介素-6(IL-6)、超氧化物歧化酶(SOD)、鐵調(diào)素(Hepc)和C反應(yīng)蛋白(CRP)水平,及不良反應(yīng)情況。結(jié)果 治療后,治療組臨床總有效率為98.46%,明顯高于對照組總有效率(84.62%,P<0.05)。治療后,治療組癥狀緩解時間均明顯早于對照組(P<0.05)。治療后,兩組患者RBC、HT、Hb、SF和SOD指標(biāo)水平明顯升高,而IL-6、Hepc、CRP水平明顯降低(P<0.05),且治療組這些指標(biāo)水平明顯好于對照組(P<0.05)。治療后,治療組不良反應(yīng)發(fā)生率為7.69%,明顯低于對照組(12.31%,P<0.05)。結(jié)論 羅沙司他聯(lián)合健脾生血片治療腎性貧血效果確切,有效改善貧血癥狀,降低炎性因子水平。

Objective To observe the clinical effect of Jianpi Shengxue Tablets combined with roxadustat in treatment of renal anemia in non-dialysis patients with chronic nephropathy. Methods Patients (130 cases) with non-dialytic renal anemia in stage 3-5 of chronic kidney disease in Henan Hongli Hospital from November 2020 to November 2022 were randomly divided into control (65 cases) and treatment (65 cases) group. Patients in the control group were po administered with Roxadustat Capsules, 70 mg/time (40-60 kg), 100 mg/time (≥ 60 kg), three times a week. Patients in the treatment group were po administered with Jianpi Shengxue Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluation was evaluated, and the relief time of symptom, the levels of RBC, HT, Hb, SF, IL-6, Hepc, CRP and SOD, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.46%, which was significantly higher than that of the control group (84.62%, P < 0.05). After treatment, the time of symptom relief in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the levels of RBC, HT, Hb, SF and SOD were significantly increased, while the levels of IL-6, Hepc and CRP were significantly decreased in two groups (P < 0.05), and the level of these indexes in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group was 7.69%, which was significantly lower than that in the control group (12.31%, P < 0.05). Conclusion Rosalastar combined with Jianpi Shengxue Tablets is effective in treatment of renal anemia, which can effectively improve the symptoms of anemia and reduce the level of inflammatory factors.

R973